p53AIP1 Expression can be a Prognostic Marker in Non-small Cell Lung Cancer

Clinical Oncology

Volumn 20, Issue 2, 2008, Pages 148-151

  Yamashita, S i ^a,b   Masuda, Y ^a   Yoshida, N ^a   Matsuzaki, H ^a   Kurizaki, T ^a   Haga, Y ^a   Ikei, S ^a   Miyawaki, M ^b   Kawano, Y ^b   Chujyo, M ^b   Kawahara, K ^b  

^a NATIONAL HOSPITAL ORGANIZATION KUMAMOTO MEDICAL CENTER   (Japan)

^b OITA UNIVERSITY   (Japan)

Author keywords

Lung cancer; p53AIP1; prognostic marker

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOSIS INDUCING FACTOR; APOPTOSIS INDUCING FACTOR 1; PROTEIN P53; RNA; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; EXON; FEMALE; GENE SEQUENCE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; POINT MUTATION; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; SQUAMOUS CELL CARCINOMA;

AGED; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION; GENES, P53; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; SMOKING; SURVIVAL ANALYSIS;

EID: 38849120532     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2007.08.006     Document Type: Article

References (14)

1. Harris C.C., and Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329 (1993) 1318-1327
2. Mitsudomi T., Hamajima N., Ogawa M., and Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 6 (2000) 4055-4063
3. Steele R.J., Thompson A.M., Hall P.A., and Lane D.P. The p53 tumour suppressor gene. Br J Surg 85 (1998) 1460-1467
4. Pfeifer G.P., Denissenko M.F., Olivier M., Tretyakova N., Hecht S.S., and Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 21 (2002) 7435-7451
5. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
6. Sionov R.V., and Haupt Y. The cellular response to p53: the decision between life and death. Oncogene 18 (1999) 6145-6157
7. Asker C., Wiman K.G., and Selivanova G. p53-induced apoptosis as a safeguard against cancer. Biochem Biophys Res Commun 265 (1999) 1-6
8. Bates S., and Vousden K.H. Mechanisms of p53-mediated apoptosis. Cell Mol Life Sci 55 (1999) 28-37
9. Oda K., Arakawa H., Tanaka T., et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102 (2000) 849-862
10. Matsuda K., Yoshida K., Taya Y., Nakamura K., Nakamura Y., and Arakawa H. p53AIP1 regulates the mitochondrial apoptotic pathway. Cancer Res 62 (2002) 2883-2889
11. Aarskog N.K., and Vedeler C.A. Real-time quantitative polymerase chain reaction. A new method that detects both the peripheral myelin protein 22 duplication in Charcot-Marie-Tooth type 1A disease and the peripheral myelin protein 22 deletion in hereditary neuropathy with liability to pressure palsies. Hum Genet 107 (2000) 494-498
12. Matsuzoe D., Hideshima T., Ohshima K., Kawahara K., Shirakusa T., and Kimura A. Discrimination of double primary lung cancer from intrapulmonary metastasis by p53 gene mutation. Br J Cancer 79 (1999) 1549-1552
13. Ohtani S., Kagawa S., Tango Y., et al. Quantitative analysis of p53-targeted gene expression and visualization of p53 transcriptional activity following intratumoral administration of adenoviral p53 in vivo. Mol Cancer Ther 3 (2004) 93-100
14. Gao W.M., Mady H.H., Yu G.Y., et al. Comparison of p53 mutations between adenocarcinoma and squamous cell carcinoma of the lung: unique spectra involving G to A transitions and G to T transversions in both histologic types. Lung Cancer 40 (2003) 141-150